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Abstract (word count = 247) 
Background & aims: Interest in Gilbert’s syndrome has increased recently following 
genetic studies showing lower rates of heart disease but higher rates of adverse 
reactions to certain drugs. We examined trends in Gilbert’s syndrome recognition 
and the association with gallstones and death using The Health Improvement 
Network primary care database. 
Methods: Patients with a diagnosis of Gilbert’s syndrome and a bilirubin level 
>17µmol/L (n=4,266) were compared to patients with similar sociodemographic 
characteristics but with a bilirubin level below 17µmol/L (n=21,968). Adjusted 
incidence rate ratios (IRRs) rates for gallstones and death were estimated.   
Results: The incidence of recorded Gilbert’s syndrome for the whole database was 
1.3/10,000 patient years (PYs) and varied according to age, gender and social 
deprivation. Over 25,000 PYs of follow-up there were 668 new cases of gallstones 
and 1174 deaths. The incidence of gallstones was 40/10,000 PYs in the Gilbert’s 
cohort compared with 25/10,000 PYs in the comparison cohort. Mortality rates were 
24/10,000 PYs in the Gilbert’s cohort versus 50/10,000 PYs in the comparison 
cohort.  Men with Gilbert’s were more likely to have gallstones than women with the 
condition (adjusted IRR: 2.2 in men [95%CI; 1.7-2.8] and 1.4 in women [95%CI; 1.0-
1.8]). Mortality rates were around half in patients with Gilbert’s syndrome (adjusted 
IRR: 0.5 [95%CI; 0.4-0.7]). 
Conclusions: Recognition of Gilbert’s syndrome is associated with factors other than 
autosomal genetic variation. Abdominal pain may be a symptom of Gilbert’s 
syndrome due to gallstones and antioxidant properties of moderately high bilirubin 
may explain lower death rates. 
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Introduction 
Gilbert’s syndrome (MIM#143500) is a common form of unconjugated 
hyperbilirubinaemia caused by an inherited deficiency in the bilirubin-conjugating 
enzyme UDP-glucuronosyltransferase 1-1 (UGT1A1) [1]. The condition is highly 
prevalent ranging from 3-12% of the population depending on the mode of diagnosis 
[1-3]. Intermittent jaundice is the only clinically recognised symptom, which can be 
triggered by infections, certain drugs and situations associated with low caloric intake 
such as gastrointestinal illness, surgery and fasting [4-7]. Some studies and patient 
information websites report that gastrointestinal symptoms and chronic fatigue are 
also symptoms [4, 8, 9] though this has not always been confirmed [10].  
Gilbert’s syndrome is historically regarded as a benign trait and clinical recognition is 
often incidental to routine laboratory investigations [11-13]. However, there has been 
renewed interest in the condition following the results from more recent genetic 
association studies. For instance, homozygosity for the gene promoter variant 
termed UGT1A1*28, which underlies the condition in Europeans [1], has been 
associated with an increased risk of developing gallstones [14-16] and also a 
predisposition to certain adverse reactions to drugs requiring UGT1A1-mediated 
glucuronidation for elimination [17]. Greatly reduced rates of cardiovascular disease 
(CVD) have also been reported for people homozygous for UGT1A1*28 [18], which 
may reflect the potent antioxidant/anti-inflammatory properties of bilirubin [18, 19]. 
Thus recognition of Gilbert’s syndrome may be useful, not only for excluding more 
serious hepatobiliary disease, but also for estimating disease risk, informing the 
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need for secondary care referrals in patients presenting with hyperbilirubinaemia and 
monitoring response to drugs requiring UGT1A-mediated glucuronidation. 
There have been no large population-based studies on Gilbert’s syndrome in the 
general population. The aim of this study was to use The Health Improvement 
Network (THIN), a United Kingdom (UK) primary care database to: 1) examine the 
recording of Gilbert’s syndrome in primary care and 2) obtain estimates of the risk of 
gallstones and death relative to patients without evidence of Gilbert’s syndrome. 
Patients and methods 
Data source 
Most general practitioners (GPs) in the UK record patient data electronically and 
some practices have opted to provide these data for clinical and epidemiological 
research. THIN primary care database provides anonymized records on over nine 
million patients registered with over 500 general practices that use the VISION 
software to record details of consultations (http://csdmruk.cegedim.com/). 
Information on diagnoses, symptoms, and referrals to secondary care are 
electronically recorded as Read codes, a hierarchical coding system used in UK 
primary care [20]. Information on prescriptions and variables such as height, weight, 
blood pressure, smoking status and laboratory test results are also recorded. The 
database provides quintiles of the Townsend score measure of social deprivation, 
which is a composite measure of owner-occupation, overcrowding, car ownership, 
and unemployment levels derived from UK census data and linked to the patient’s 
postal code. THIN data is broadly representative of the UK general practice 
population in terms of demographics and consultation behaviour [21]. Clinical 
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diagnoses recorded by GPs electronically have recently been shown to be accurate 
compared with other reliable sources [22].  
A cohort design was used to examine trends in recording of new cases of Gilbert’s 
syndrome between January 1st 2000 and December 31st 2010.  A diagnosis of 
Gilbert’s syndrome was ascertained by the presence of the relevant Read code 
“C374200”. Incident cases were defined using published methodology [23]. In brief, 
diagnosis rates in newly registered patients were plotted over 365 days. Initially there 
is a spike in recording rates of Gilbert’s syndrome just after registration suggesting 
GPs were entering existing diagnoses in newly registered patients.  However, six 
months after registration the recording rate stabilized and we followed patients up 
from the latest date of six months after practice registration, the start of the study 
period (January 1st 2000) or the date when the practice were deemed to record 
mortality at acceptable rates (AMR date) [24]. Patients exited at the earliest date of 
Gilbert’s diagnosis, the end of the study period (December 31st 2010), death or 
transfer to a different practice. 
A cohort design was also used to compare rates of symptoms and clinical outcomes 
in patients with Gilbert’s syndrome to those without evidence of Gilbert’s syndrome. 
All patients with an abnormal bilirubin level (>17 µmol/L) and a Read code diagnosis 
of Gilbert’s syndrome were extracted. Within each general practice, a comparison 
cohort with normal bilirubin levels (≤17 µmol/L) was extracted using stratified 
sampling to ensure similar characteristics in terms of age, sex and year of bilirubin 
test. Up to six comparator patients were selected per patient with Gilbert’s syndrome. 
For each outcome of interest, patients entered the cohort using the same criteria as 
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above.  Patients exited the earliest date of the event of interest, the end of the study 
period (December 31st 2010), death or transfer to a different practice. 
Outcomes 
The rates of gallstones and all-cause mortality were compared in the two cohorts. A 
Read code lists for gallstones including cholecystectomy was developed using a 
previously reported method [25]. Incident events were defined using a method 
similar to that used for defining new cases of Gilbert’s syndrome described above 
[23]. Death was ascertained by the presence of a date of death in the patient 
records.  
Covariates 
General health indicators previously associated with bilirubin levels were selected as 
covariates as these may influence a diagnosis of Gilbert’s syndrome. These included 
smoking status, body mass index (BMI), blood pressure, alanine aminotransferase 
(ALT), alkaline phosphatise (ALP), and the Townsend score of social deprivation. 
Where multiple values had been recorded, that taken closest to the bilirubin test date 
was selected. Age, gender and time period were also included to account for any 
imbalances in the stratified sampling.  
Statistical analyses 
Incidence rates of Gilbert’s syndrome were calculated across age, gender, time 
period and social deprivation assuming a Poisson distribution, which is appropriate 
for count data when the event is rare. Multivariable Poisson regression was used to 
calculate adjusted incidence rate ratios (IRRs) of events in the Gilbert’s syndrome 
cohort versus the comparison cohort. A complete-case analysis was done with 
continuous covariates entered into the model. To account for data clustering within 
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GP practice we used a random effect regression model.  Some studies report that 
the protection against CVD and the risk of gallstones in patients with UGT1A1 
deficiency/hyperbilirubinemia may differ across gender [14, 26]. Therefore the 
likelihood ratio test was used to compare nested models with and without interaction 
terms between Gilbert’s syndrome and gender.  
The THIN Scheme was approved by the National Health Service South-East Multi-
centre Research Ethics Committee (MREC) and the present study was approved by 
the Cambridgeshire MREC. 
Results 
The overall incidence of Gilbert’s syndrome during the study period was 1.3 per 
10,000 patient years (95% CI; 1.2-1.3). The prevalence in 2010 (i.e. any patient 
actively contributing data to THIN in 2010 with a diagnosis in their medical history) 
was 8.0 per 10,000 persons (95% CI; 7.8-8.2). Since 2000 there has been a general 
increase in new diagnoses for both men and women with a peak in 2005 and a slight 
decline in males thereafter (Figure 1). Diagnosis was around two-thirds higher in 
males than in females and the distribution of age at first recognised diagnosis was 
quite different across the genders (Figure 1).  For males, there was a clear peak in 
diagnosis at around age 60-70 whereas for women the peak in diagnosis was at age 
band 30-40. There was a trend for lower diagnosis rates in more deprived postcode 
areas, which was particularly strong for males with those in the most affluent 
postcode areas having more than double the incidence rate of Gilbert’s syndrome. 
This trend remained strong (p<0.001) after accounting for differences in age and 
time period across social deprivation levels in a multivariable Poisson regression 
model. 
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The characteristics of the Gilbert’s cohort (n=4,266) and the comparison cohort 
(n=21,968) were very similar except for a lower proportion of smokers in the Gilbert’s 
cohort (Table 1).  Over a total of 25,000 PYs of follow-up there were 668 new cases 
of gallstones and 1174 deaths. The incidence of gallstones was 40/10,000 PYs in 
the Gilbert’s cohort compared with 25/10,000 PYs in the comparison cohort. There 
was a significant interaction between Gilbert’s syndrome, gender and the risk of 
gallstones. A stratified analysis showed that the relative risk of gallstones was over 
double in men with Gilbert’s syndrome compared to 36% higher in women with 
Gilbert’s syndrome after adjustment for potential confounders (Table 2). The main 
reason for the increase in effect size after the addition of potential confounders was 
the negative confounding effect of BMI. Removing ALT from the regression model, 
which may be on the causal pathway, did not alter the results. Mortality rates in 
people with Gilbert’s syndrome were almost half those of the comparison cohort after 
accounting for potential confounding factors (Table 2). Adjusting for major 
comorbidity (depression, diabetes, heart disease) did not materially alter the findings. 
Discussion 
This study is the largest population-based analysis of diagnosed Gilbert’s syndrome. 
We report that diagnosis is more common in men and often first identified later in life. 
Those with a diagnosis tend to have higher rates of gallstones but a much lower risk 
of mortality compared to patients without evidence of the condition.  
The magnitude of the differences in rates of gallstones in the THIN cohorts is similar 
to reports for healthy Europeans homozygous for a variant in complete LD with 
UGT1A1*28 compared to those without the genotype [14]. This European study also 
reported an interaction with gender where the odds in men homozygous for a variant 
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in complete linkage disequilibrium with UGT1A1*28 were 2.3 versus other genotypes 
whereas the odds for women were only 1.1 and non-significant [14]. Furthermore, 
this finding was replicated in a sample of South American men and women [14]. 
Cohort studies in children and adults with inherited haemolytic anaemia, already 
predisposed to high bilirubin levels due to haemolysis, report similar associations by 
genotype with those homozygous for UGT1A1*28 having 2-3 times higher rates of 
gallstones and gallstone surgery [15, 16].  The magnitude of the results from these 
studies is similar to our own and a higher risk of gallstones could explain why 
abdominal pain is sometimes cited as a symptom of Gilbert’s syndrome.  
Recognition of Gilbert’s syndrome prior to gallstone surgery could be useful to 
prevent repeat operations in patients with post-surgery jaundice brought on by 
fasting. 
This is the first study to report comparative mortality rates in patients with Gilbert’s 
syndrome and those without evidence of the condition. The 50% lower mortality 
rates observed in patients with Gilbert’s syndrome could reflect the systemic 
antioxidant/anti-inflammatory properties of serum bilirubin [19, 27-31]. The 
Framingham offspring Cohort study reported that CVD rates were 64% lower in 
patients homozygous for UGT1A1*28 compared with the other genotypes [18]. While 
the lower mortality rates in the Gilbert’s cohort may reflect protection against CVD, 
the major cause of death in the UK, it is possible that protection from other disease 
related to oxidative stress and inflammation such as diabetes and respiratory 
disease, also contribute to the relationship.  
Although recognition has generally increased over time, the recording of Gilbert’s 
syndrome by GPs is markedly lower than the prevalence of the UGT1A1 genotype, 
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which is present in around 10% in European populations [18]. The under-diagnosis 
most probably represents the lack of presentation with specific symptoms, the 
difficulty establishing a definitive diagnosis without genetic testing and the low clinical 
utility of diagnosing a condition that is perceived to be relatively benign.  
Most studies also report that Gilbert’s syndrome is 50-75% more prevalent in men [2, 
32]. This could be explained by the higher average levels of bilirubin in men 
compared with women and also the more dramatic response to environmental 
factors such as fasting. For example, the increase in unconjugated bilirubin levels 
following a 400-calorie restricted diet over 24 hours was 27.4µmol/L in men with 
Gilbert’s syndrome versus 10.8µmol/l in women [13]. Similarly, diagnosis rates are 
probably higher in non-smokers and in areas of lower social deprivation (where 
smoking is less common) because bilirubin levels are more likely to exceed the 
diagnostic thresholds [33]. Rates may also be higher is less socially deprived areas 
because patients have lower rates of co-morbidity that might otherwise mask more 
benign traits like Gilbert’s syndrome or patients are better informed and more likely 
to pursue a diagnosis. The finding that diagnosed cases tend to be healthier in terms 
of lower BMI, non-smoking status and lower social deprivation is important when 
considering earlier studies comparing clinical characteristics in patients with Gilbert’s 
syndrome diagnosed by exclusion criteria alone to control groups that were either 
unmatched or matched only on age and sex. 
The average age of diagnosis in studies from over 20 years ago is generally reported 
as the mid-thirties [12, 13, 34]. The relatively late age of diagnosis in this study 
suggests Gilbert’s syndrome is largely an incidental finding during routine lab tests in 
the modern clinical setting. The high diagnosis rate in women between ages 20-40 
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could represent routine testing and increased consultation during pregnancy. The 
high rate around the age of 60 in both men and women may represent incidental 
diagnoses during routine health checks and liver function testing for drug monitoring 
such as prior to statin prescription. 
 The major strength of this study is the sample size. The data are broadly 
representative of the UK and the prevalence and incidence of recognised Gilbert’s 
syndrome is probably a fairly accurate reflection of national rates. However, GPs 
record data for the purpose of patient management and some variables useful for 
researchers but not directly relevant for patient care, have high levels of missing 
data. Ethnicity may have also influenced diagnosis of Gilbert’s syndrome and be 
unbalanced in the two cohorts but is not well recorded in primary care. However, the 
UK is over 92% white European and this is unlikely to be a strong source of 
confounding. There are also limitations on the generalisability of the findings.  For 
instance, the results cannot be generalised to all patients with Gilbert’s syndrome 
because most are undiagnosed and the group we have examined may be a more 
severe subset with additional genetic variation of UGT1A1 or other enzymes 
associated with bilirubin elimination. The cohorts were restricted to patients with 
bilirubin tests in their medical history and although bilirubin testing is now fairly 
routine in the UK, they may still represent a less healthy sub-population. 
Due to the phenomenon of linkage disequilibrium, most UGT1A1*28 homozygotes 
also have deficiencies in other UGT1A isoforms encoded just downstream of 
UGT1A1 [35]. All UGT1A isoforms are drug metabolising enzymes and a number of 
pharmacogenetic studies and investigations in patients with Gilbert’s syndrome 
suggest altered glucuronidation capacity toward a range of common agents including 
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aspirin, paracetamol and statins [35-37].  Given the high prevalence of the genetic 
variation underlying Gilbert’s syndrome and the high burden of adverse reactions to 
these agents, further research into drug response is warranted. For instance, the 
Food and Drug Administration recommends UGT1A1*28 testing to identify patients 
at high risk of life-threatening toxicity to the chemotherapy agent irinotecan [38].   
In summary, recognised Gilbert’s syndrome in the primary care setting has generally 
increased over time and is higher in men and people living in less socially deprived 
areas. Patients with a record of Gilbert’s syndrome have higher rates of gallstones 
but lower mortality from any cause. In addition, pharmacogenetic studies on the 
response to commonly prescribed drugs requiring glucuronidation by UGT1A 
enzymes is warranted to understand the risk of drug toxicity and whether wider 
recognition of the condition would be beneficial to patients and GPs. 
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Table 1: Baseline characteristics of a cohort with recognised Gilbert’s syndrome and a comparison 
cohort selected to have similar age and gender distribution but bilirubin levels ≤17 µmol/L. 
 Gilbert’s cohort Comparison cohort 
 (n=4,266) (n=21,968) 
Male (%) 2,871 (67) 14,711 (67) 
 Median (IQR) Median (IQR) 
Serum total bilirubin  µmol/L 29 (24-37) 10 (7-12) 
Follow-up in years  9 (5-12) 9 (5-12) 
Age at bilirubin test 48 (35-61) 49 (36-61) 
Consultation rate * 18 (10-28) 17 (9-29) 
BMI  24.9 (22.3-27.8) 26.0 (23.2-29.5) 
DBP, mmHg 80 (70-86) 80 (71-88) 
SBP, mmHg 130 (120-143) 130 (120-145) 
ALP, IU/L 71 (57-91) 76 (61-99) 
ALT, IU/L 24 (17-33) 25 (18-36) 
Smoking status (%)   
Current 427 (10) 6,250 (28) 
Ex 800 (19) 4,252 (19) 
Never  3,039(71) 11,466 (52) 
Social deprivation score (%)   
1 (least deprived)  1,402 (33) 6,192 (28) 
2 1,104 (26)  5,132 (23) 
3 856 (20)  4,671 (21) 
4 622 (15) 3,795 (17) 
5 (most deprived) 282 (7) 2,178 (10) 
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase ; BMI, body mass index; DBP, diastolic blood 
pressure; SBP, systolic blood pressure; SD, standard deviation. 
* Median consultations in the two years prior to the bilirubin test 
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Table 2: Incidence of gallstones and death in a cohort of patients with Gilbert’s syndrome and a 
comparison cohort without evidence of the condition. The results of the multivariable Poisson regression 
are shown stratified on gender for gallstones due to the presence of effect modification. 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; PYs, person years 
* Model 1=age, gender, time period 
** Model 2=multivariable analysis adjusting for age, gender, time period, blood pressure, body mass index, alanine 
aminotransferase, alkaline phosphatase, and social deprivation index. 
 
 
    Gallstones Death 
    Men Women  
Gilbert's cohort 
  
Events/PYs (per 10,000) 93/2.6 59/1.2 97/4.05 
Incidence rate (95%CI) 
35.6  
(29.1-43.6) 
48.7  
(37.7-62.9) 
23.9  
(19.6-29.2) 
Comparison cohort 
  
Events/PYs (per 10,000) 244/14.1 272/6.7 1077/21.6 
Incidence rate (95%CI) 
17.3  
(15.3-19.6) 
36.0  
(36.0-45.7) 
49.8  
(46.9-52.9) 
Model 1 * IRR (95%CI) 
1.96  
(1.54-2.49) 
1.13  
(0.85-1.50) 
0.43  
(0.34-0.55) 
  p-value <0.001 0.39 <0.001 
Model 2 ** IRR (95%CI) 
2.17  
(1.68-2.79) 
1.36  
(1.01-1.82) 
0.53  
(0.40-0.66) 
  p-value <0.001 0.04 <0.001 
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Fig. 1. The incidence of recognised Gilbert’s syndrome in the UK primary care setting across 
sociodemographic variables.  
Time period (A), age band (B) and social deprivation score (C). Error bars represent 95% confidence intervals. 
 
 
